NCT07562022 A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
| NCT ID | NCT07562022 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Sinocelltech Ltd. |
| Condition | Follicular Lymphoma (FL) |
| Study Type | INTERVENTIONAL |
| Enrollment | 93 participants |
| Start Date | 2026-06-09 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 93 participants in total. It began in 2026-06-09 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular lymphoma (FL).
Eligibility Criteria
Inclusion Criteria: * Age 18-80 years old * Histologically confirmed Follicular lymphoma (FL) grade 1, 2, or 3a according to WHO 2022 criteria * Relapsed or refractory (R/R) disease to at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy * Judged by the investigator, the participant must urgently need to receive systemic treatment, based on meeting at least one GELF criterion * A measurable or evaluable disease at the time of enrolment * ECOG PS 0-2 * Adequate organ function and bone marrow function * Expected survival ≥ 6 months Exclusion Criteria: * Documented refractoriness to lenalidomide. * Have lenalidomide exposure within 12 months prior to randomization
Frequently Asked Questions
Who can join the NCT07562022 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Follicular Lymphoma (FL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07562022 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 93 participants.
Is NCT07562022 currently recruiting?
Yes, NCT07562022 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sinocelltech Ltd. to inquire about joining.
Where is the NCT07562022 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07562022 clinical trial?
NCT07562022 is sponsored by Sinocelltech Ltd.. The trial plans to enroll 93 participants.